Abstract Treatment of chronic myeloid leukemia has improved significantly with the
introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines based on …

Simple Summary Outcome of patients with Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL) dramatically improved during the past 20 years with the …

How to best use tyrosine kinase inhibitors (TKIs) of BCR-ABL after allogeneic stem cell
transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) …

The year 2020 marked the 30th anniversary of the Nobel Prize in Medicine awarded to E.
Donnall Thomas for the development of allogeneic hematopoietic stem cell transplantation …

目前造血干细胞移植已成为急性白血病治疗中不可或缺的组成部分. 虽然过去20
年来靶向治疗及免疫治疗迅速发展, 提高了急性白血病的疗效, 但造血干细胞移植的治疗地位 …

Disease relapse is the leading cause of failure for patients receiving allogeneic
hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo …

Purpose: The anti-leukemic activity of allogeneic hematopoietic cell transplantation (HCT)
depends on both the intensity of conditioning regimen and the strength of the graft-versus …

Relapse is a major cause of treatment failure in Philadelphia-chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL) undergoing allogeneic hematopoietic cell transplantation …

Background For patients undergoing allogeneic hematopoietic stem cell transplant (HSCT)
for acute myeloid leukemia (AML), disease relapse remains the most common reason for …

The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with
the incorporation of multi-agent chemotherapy in the treatment landscape as well as the …